Free Trial

ADC Therapeutics (ADCT) Stock Price, News & Analysis

-0.31 (-7.54%)
(As of 02:03 PM ET)
Today's Range
50-Day Range
52-Week Range
651,023 shs
Average Volume
723,576 shs
Market Capitalization
$314.55 million
P/E Ratio
Dividend Yield
Price Target

ADC Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
94.9% Upside
$7.25 Price Target
Short Interest
1.43% of Float Sold Short
Dividend Strength
News Sentiment
0.57mentions of ADC Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$133,195 Sold Last Quarter
Proj. Earnings Growth
From ($1.86) to ($1.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.08 out of 5 stars

Medical Sector

343rd out of 921 stocks

Pharmaceutical Preparations Industry

148th out of 419 stocks

ADCT stock logo

About ADC Therapeutics Stock (NYSE:ADCT)

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADCT Stock Price History

ADCT Stock News Headlines

ADCT ADC Therapeutics SA
Q4 2023 ADC Therapeutics SA Earnings Call
See More Headlines
Receive ADCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$68.62 million
Book Value
($1.93) per share


Free Float
Market Cap
$321.17 million
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Ameet Mallik M.B.A. (Age 51)
    M.S., CEO & Director
    Comp: $1.84M
  • Mr. Jose I. Carmona M.B.A. (Age 52)
    Chief Financial Officer
    Comp: $884.86k
  • Dr. Mohamed Zaki M.D. (Age 59)
    Ph.D., Chief Medical Officer
    Comp: $2.41M
  • Ms. Lisa Michelle Kallebo
    Corporate Controller & Chief Accounting Officer
  • Dr. Michael Mulkerrin Ph.D. (Age 69)
    Chief Technical Operations Officer
  • Dr. Patrick van Berkel Ph.D. (Age 56)
    Chief Scientific Officer
  • Amanda Hamilton
    Investor Relations Officer
  • Mr. Peter J. Graham Esq. (Age 57)
    Chief Legal Officer
  • Ms. Eugenia Litz
    Vice President of Investor Relations & Corporate Communications
  • Ms. Kimberly Pope (Age 57)
    Senior VP & Chief People Officer

ADCT Stock Analysis - Frequently Asked Questions

Should I buy or sell ADC Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ADCT shares.
View ADCT analyst ratings
or view top-rated stocks.

What is ADC Therapeutics' stock price target for 2024?

5 Wall Street research analysts have issued 1-year price objectives for ADC Therapeutics' shares. Their ADCT share price targets range from $2.00 to $11.00. On average, they anticipate the company's stock price to reach $7.25 in the next year. This suggests a possible upside of 94.9% from the stock's current price.
View analysts price targets for ADCT
or view top-rated stocks among Wall Street analysts.

How have ADCT shares performed in 2024?

ADC Therapeutics' stock was trading at $1.66 on January 1st, 2024. Since then, ADCT shares have increased by 124.1% and is now trading at $3.72.
View the best growth stocks for 2024 here

Are investors shorting ADC Therapeutics?

ADC Therapeutics saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 888,100 shares, a drop of 10.6% from the March 31st total of 993,100 shares. Based on an average trading volume of 733,600 shares, the days-to-cover ratio is currently 1.2 days. Currently, 1.6% of the company's stock are sold short.
View ADC Therapeutics' Short Interest

When is ADC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our ADCT earnings forecast

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) posted its earnings results on Monday, May, 6th. The company reported ($0.56) EPS for the quarter, meeting the consensus estimate of ($0.56). The company had revenue of $18.05 million for the quarter, compared to the consensus estimate of $18.19 million. ADC Therapeutics had a negative net margin of 330.17% and a negative trailing twelve-month return on equity of 1,313.37%. During the same period in the prior year, the business earned ($0.74) EPS.

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).

When did ADC Therapeutics IPO?

ADC Therapeutics (ADCT) raised $126 million in an initial public offering on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO.

Who are ADC Therapeutics' major shareholders?

ADC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Redmile Group LLC (18.45%), Hennion & Walsh Asset Management Inc. (0.09%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends

How do I buy shares of ADC Therapeutics?

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ADCT) was last updated on 5/21/2024 by Staff

From Our Partners